Withycombe JS, Kubaney HR, Okada M, Yun CS, Gupta S, Bloom C, Parker V, Rau RE, Zupanec S. Delivery of Care for Pediatric Patients Receiving Blinatumomab: A Children’s Oncology Group Study. Cancer Nurs. 2024 Nov-Dec 01;47(6):451-459. doi: 10.1097/NCC.0000000000001309. Epub 2023 Nov 22. PubMed PMID: 38016041; PubMed Central PMCID: PMC11128477.
Study ID Citation
Abstract
Blinatumomab is an immunotherapy agent utilized in pediatric oncology for the treatment of B-lineage Acute Lymphoblastic Leukemia (B-ALL). Administration of blinatumomab, via continuous 28-day infusion cycles, can present multiple decision points and challenges related to patient care. Nurses are at the forefront of coordinating and delivering care for patients receiving blinatumomab. To describe the current state of practice across Children’s Oncology Group (COG) member institutions regarding blinatumomab administration in both inpatient and home/outpatient settings.